Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 583-586, 2011.
Article
in Chinese
| WPRIM
| ID: wpr-251521
ABSTRACT
<p><b>OBJECTIVE</b>To compare the efficacy of two different regimens of low doses rituximab for the treatment of adult patients with immune thrombocytopenia (ITP).</p><p><b>METHODS</b>Fifty-one patients were enrolled in this study and was non-randomly assigned to receive 100 mg rituximab weekly for 4 weeks (group A, 31 cases) or a single dose of 375 mg/m2 rituximab (group B, 20 cases).</p><p><b>RESULTS</b>For group A Overall and complete response (OR and CR) rates were 58% and 29% , respectively. In responders, the median time to response was 42 (10 -101) days, with a median follow-up time of 15 (10 - 16) months, 3 of 18 responders (17%) relapsed. For group B OR and CR rates were 50% and 35% , respectively. In responders, the median time to response was 35 (18 - 108) days, with a median follow-up time of 13 (6 -17) months, 1 of 9 responders (11%) relapsed. No significant difference in the OR, CR, the relapse rate and relapse free survival was observed in patients between the two groups.</p><p><b>CONCLUSION</b>The low dose rituximab regimen (100 mg weekly for 4 weeks or a single close of 375 mg/m2) may be a useful alternative therapy in patients with ITP.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thrombocytopenia
/
Treatment Outcome
/
Therapeutic Uses
/
Dose-Response Relationship, Drug
/
Drug Therapy
/
Antibodies, Monoclonal, Murine-Derived
/
Rituximab
/
Antibodies, Monoclonal
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS